Statins and autoimmunity: State-of-the-art.

Animals Anti-Inflammatory Agents / adverse effects Anticholesteremic Agents / adverse effects Autoimmune Diseases / drug therapy Autoimmunity / drug effects Biomarkers / blood Cholesterol, LDL / blood Dyslipidemias / blood Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects Immune System / drug effects
Autoimmune diseases Immunomodulation Statins

Journal

Pharmacology & therapeutics
ISSN: 1879-016X
Titre abrégé: Pharmacol Ther
Pays: England
ID NLM: 7905840

Informations de publication

Date de publication:
10 2020
Historique:
received: 01 04 2020
accepted: 09 06 2020
pubmed: 28 6 2020
medline: 8 7 2021
entrez: 28 6 2020
Statut: ppublish

Résumé

HMG-CoA reductase inhibitors, or statins, are potent plasma LDL-cholesterol (LDL-c) lowering agents. Since the introduction of the first statin, lovastatin, in 1987, accumulating evidence showed that non-cholesterol lowering effects play an important role in their efficacy to reduce atherosclerotic cardiovascular disease (ASCVD). Thus, these non-LDL-c lowering properties could benefit patients with immune-mediated diseases. Statins and their associated immune-modulating roles have recently received much attention. Different statins have been administered in various experimental and clinical studies focused on autoimmunity. The results indicate that statins can modulate immune responses through mevalonate pathway-dependent and -independent mechanisms. The anti-inflammatory and immune-modulating effects include cell adhesion, migration of antigen presenting cells, and differentiation, as well as activation, of T-cells. In various autoimmune diseases (e.g. rheumatoid arthritis, lupus, and multiple sclerosis), promising results have been obtained to date.

Identifiants

DOI: 10.1016/j.pharmthera.2020.107614 PMID: 32592715
pubmed: 32592715
pii: S0163-7258(20)30144-3
doi: 10.1016/j.pharmthera.2020.107614
pii:
doi:

Substances chimiques

Anti-Inflammatory Agents 0
Anticholesteremic Agents 0
Biomarkers 0
Cholesterol, LDL 0
Hydroxymethylglutaryl-CoA Reductase Inhibitors 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

107614

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Sajad Dehnavi (S)

Department of Immunology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Nasrollah Sohrabi (N)

Department of Medical Laboratory Sciences, School of Paramedicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Mahvash Sadeghi (M)

Department of Immunology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Peter Lansberg (P)

Department of Pediatrics, Section Molecular Genetics, University Medical Center Groningen, Building 3226, Room 04.14, Internal Zip Code EA12, Antonius Deusinglaan 19713 AV, Groningen, The Netherlands.

Maciej Banach (M)

Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, Lodz, Poland; Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland.

Khalid Al-Rasadi (K)

Department of Clinical Biochemistry, Sultan Qaboos University Hospital, Muscat, Oman.

Thomas P Johnston (TP)

Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO, United States. Electronic address: johnstont@umkc.edu.

Amirhossein Sahebkar (A)

Halal Research Center of IRI, FDA, Tehran, Iran; Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: sahebkara@mums.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Statins and autoimmunity: State-of-the-art.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-inflammatoires › Statins and autoimmunity: State-of-the-art.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents régulateurs du métabolisme des lipides › Hypolipémiants › Anticholestérolémiants › Statins and autoimmunity: State-of-the-art.
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Statins and autoimmunity: State-of-the-art.
questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Auto-immunité › Statins and autoimmunity: State-of-the-art.
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Statins and autoimmunity: State-of-the-art.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Lipoprotéines › Lipoprotéines LDL › Cholestérol LDL › Statins and autoimmunity: State-of-the-art.
questionsmedicales.fr › Maladies métaboliques et nutritionnelles › Maladies métaboliques › Troubles du métabolisme lipidique › Dyslipidémies › Statins and autoimmunity: State-of-the-art.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Statins and autoimmunity: State-of-the-art.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents régulateurs du métabolisme des lipides › Hypolipémiants › Anticholestérolémiants › Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase › Statins and autoimmunity: State-of-the-art.
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Statins and autoimmunity: State-of-the-art.